1.

Record Nr.

UNINA9910709789003321

Autore

Mead Jaylee M.

Titolo

Future of ultraviolet astronomy based on six years of IUE research : proceedings of a symposium held at NASA Goddard Space Flight Center, Greenbelt, Maryland, April 3-5, 1984 / / edited by Jaylee M. Mead, Robert D. Chapman, and Yoji Kondo

Pubbl/distr/stampa

Washington, D.C. : , : National Aeronautics and Space Administration, Scientific and Technical Information Branch, , 1984

Descrizione fisica

1 online resource (xiv, 544 pages) : illustrations

Collana

NASA conference publication ; ; 2349

Classificazione

39.19

Soggetti

Astronomy

Ultraviolet astronomy

Galaxies

Nebulae

Hot stars

Solar system

Astronomy - Observations

Conference papers and proceedings.

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

"December 1984."

Nota di bibliografia

Includes bibliographical references.



2.

Record Nr.

UNINA9910576878903321

Autore

Handgretinger Rupert

Titolo

Advance in the Treatment of Pediatric Leukemia

Pubbl/distr/stampa

Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022

Descrizione fisica

1 online resource (300 p.)

Soggetti

Chemistry

Research & information: general

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Sommario/riassunto

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15-20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to



chemotherapy is most important for therapy guidance. The book also provides updates and guidance  for the treatment of CML and JMML.